207 related articles for article (PubMed ID: 25016694)
21. MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1.
Wang D; Ren J; Ren H; Fu JL; Yu D
Acta Pharmacol Sin; 2018 Jan; 39(1):124-131. PubMed ID: 28816236
[TBL] [Abstract][Full Text] [Related]
22. The ratio of FoxA1 to FoxA2 in lung adenocarcinoma is regulated by LncRNA HOTAIR and chromatin remodeling factor LSH.
Wang R; Shi Y; Chen L; Jiang Y; Mao C; Yan B; Liu S; Shan B; Tao Y; Wang X
Sci Rep; 2015 Dec; 5():17826. PubMed ID: 26658322
[TBL] [Abstract][Full Text] [Related]
23. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
24. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.
Nucera C; Eeckhoute J; Finn S; Carroll JS; Ligon AH; Priolo C; Fadda G; Toner M; Sheils O; Attard M; Pontecorvi A; Nose V; Loda M; Brown M
Clin Cancer Res; 2009 Jun; 15(11):3680-9. PubMed ID: 19470727
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of the HSP72 by Foxa1 in MCF-7 human breast cancer cell line.
Song L; Xu Z; Zhang C; Qiao X; Huang C
Biochem Biophys Res Commun; 2009 Aug; 386(1):30-4. PubMed ID: 19486887
[TBL] [Abstract][Full Text] [Related]
26. Roles and correlation of FOXA1 and ZIC1 in breast cancer.
Zhang YW; Ma J; Shi CT; Han W; Gao XJ; Zhou MH; Ding HZ; Wang HN
Curr Probl Cancer; 2020 Oct; 44(5):100559. PubMed ID: 32115254
[TBL] [Abstract][Full Text] [Related]
27. Expression and prognosis analyses of forkhead box A (FOXA) family in human lung cancer.
Huang C; Liu J; Xiong B; Yonemura Y; Yang X
Gene; 2019 Feb; 685():202-210. PubMed ID: 30415009
[TBL] [Abstract][Full Text] [Related]
28. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
Horimoto Y; Arakawa A; Harada-Shoji N; Sonoue H; Yoshida Y; Himuro T; Igari F; Tokuda E; Mamat O; Tanabe M; Hino O; Saito M
Br J Cancer; 2015 Jan; 112(2):345-51. PubMed ID: 25422910
[TBL] [Abstract][Full Text] [Related]
29. FoxA1 as a lineage-specific oncogene in luminal type breast cancer.
Yamaguchi N; Ito E; Azuma S; Honma R; Yanagisawa Y; Nishikawa A; Kawamura M; Imai J; Tatsuta K; Inoue J; Semba K; Watanabe S
Biochem Biophys Res Commun; 2008 Jan; 365(4):711-7. PubMed ID: 18039470
[TBL] [Abstract][Full Text] [Related]
30. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
31. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M; Dowhan DH
Neoplasia; 2012 Apr; 14(4):283-96. PubMed ID: 22577344
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of TRPS1 stimulates epithelial-mesenchymal transition and metastasis through repression of FOXA1.
Huang JZ; Chen M; Zeng M; Xu SH; Zou FY; Chen D; Yan GR
J Pathol; 2016 Jun; 239(2):186-96. PubMed ID: 26969828
[TBL] [Abstract][Full Text] [Related]
33. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
[TBL] [Abstract][Full Text] [Related]
34. Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer.
Milevskiy MJ; Al-Ejeh F; Saunus JM; Northwood KS; Bailey PJ; Betts JA; McCart Reed AE; Nephew KP; Stone A; Gee JM; Dowhan DH; Dray E; Shewan AM; French JD; Edwards SL; Clark SJ; Lakhani SR; Brown MA
Hum Mol Genet; 2016 Aug; 25(15):3269-3283. PubMed ID: 27378691
[TBL] [Abstract][Full Text] [Related]
35. FOXA1 reprograms the TGF-β-stimulated transcriptional program from a metastasis promoter to a tumor suppressor in nasopharyngeal carcinoma.
Li J; Wang W; Chen S; Cai J; Ban Y; Peng Q; Zhou Y; Zeng Z; Li X; Xiong W; Li G; Yi M; Xiang B
Cancer Lett; 2019 Feb; 442():1-14. PubMed ID: 30392786
[TBL] [Abstract][Full Text] [Related]
36. Increased SOX2 expression in less differentiated breast carcinomas and their lymph node metastases.
Huang YH; Luo MH; Ni YB; Tsang JY; Chan SK; Lui PC; Yu AM; Tan PH; Tse GM
Histopathology; 2014 Mar; 64(4):494-503. PubMed ID: 24382260
[TBL] [Abstract][Full Text] [Related]
37. Expression of Sox2 in breast cancer cells promotes the recruitment of M2 macrophages to tumor microenvironment.
Mou W; Xu Y; Ye Y; Chen S; Li X; Gong K; Liu Y; Chen Y; Li X; Tian Y; Xiang R; Li N
Cancer Lett; 2015 Mar; 358(2):115-123. PubMed ID: 25444903
[TBL] [Abstract][Full Text] [Related]
38. A subtype of oral, laryngeal, esophageal, and lung, squamous cell carcinoma with high levels of TrkB-T1 neurotrophin receptor mRNA.
Zhou Y; Sinha S; Schwartz JL; Adami GR
BMC Cancer; 2019 Jun; 19(1):607. PubMed ID: 31221127
[TBL] [Abstract][Full Text] [Related]
39. Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas.
Bochen F; Adisurya H; Wemmert S; Lerner C; Greiner M; Zimmermann R; Hasenfus A; Wagner M; Smola S; Pfuhl T; Bozzato A; Al Kadah B; Schick B; Linxweiler M
Oncotarget; 2017 Jan; 8(3):4922-4934. PubMed ID: 28002801
[TBL] [Abstract][Full Text] [Related]
40. NONO Is a Negative Regulator of
Liang S; Takahashi H; Hirose T; Kuramitsu Y; Hatakeyama S; Yoshiyama H; Wang R; Hamada JI; Iizasa H
Cancer Genomics Proteomics; 2020; 17(4):359-367. PubMed ID: 32576581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
